Drug
Enzalutamide
Enzalutamide: highest development phase Approved, developed by Astellas, Corcept Therapeutics, Pfizer and others. 10 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Astellas, Corcept Therapeutics, Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| ENZALUTAMIDE | Approved | |
| Enzalutamide NCT02319837 | Phase 3 | Hormone Sensitive Prostate Cancer |
| enzalutamide NCT01949337 | Phase 3 | Adenocarcinoma of the Prostate |
| Enzalutamide NCT02446405 | Phase 3 | Prostatic Neoplasms |
| Enzalutamide NCT02288936 | Phase 2 | Hormone-refractory Prostate Cancer |
| enzalutamide NCT02057939 | Phase 2 | Prostate Cancer |
| Enzalutamide NCT02346578 | Phase 2 | Castration-resistant Prostate Cancer |
| Enzalutamide NCT02507570 | Phase 2 | Prostate Carcinoma Metastatic to the Bone |
| enzalutamide NCT04094519 | Phase 1 | Prostate Cancer |
| Enzalutamide NCT03674814 | Phase 1 | Prostate Cancer |
Latest
No recent events.
Follow Enzalutamide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.